136 related articles for article (PubMed ID: 16434397)
1. A pathway of structural changes produced by monastrol binding to Eg5.
Maliga Z; Xing J; Cheung H; Juszczak LJ; Friedman JM; Rosenfeld SS
J Biol Chem; 2006 Mar; 281(12):7977-82. PubMed ID: 16434397
[TBL] [Abstract][Full Text] [Related]
2. Monastrol inhibition of the mitotic kinesin Eg5.
Cochran JC; Gatial JE; Kapoor TM; Gilbert SP
J Biol Chem; 2005 Apr; 280(13):12658-67. PubMed ID: 15665380
[TBL] [Abstract][Full Text] [Related]
3. Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation.
Wojcik EJ; Dalrymple NA; Alford SR; Walker RA; Kim S
Biochemistry; 2004 Aug; 43(31):9939-49. PubMed ID: 15287721
[TBL] [Abstract][Full Text] [Related]
4. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5.
Maliga Z; Kapoor TM; Mitchison TJ
Chem Biol; 2002 Sep; 9(9):989-96. PubMed ID: 12323373
[TBL] [Abstract][Full Text] [Related]
5. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition.
Luo L; Carson JD; Dhanak D; Jackson JR; Huang PS; Lee Y; Sakowicz R; Copeland RA
Biochemistry; 2004 Dec; 43(48):15258-66. PubMed ID: 15568818
[TBL] [Abstract][Full Text] [Related]
7. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.
DeBonis S; Simorre JP; Crevel I; Lebeau L; Skoufias DA; Blangy A; Ebel C; Gans P; Cross R; Hackney DD; Wade RH; Kozielski F
Biochemistry; 2003 Jan; 42(2):338-49. PubMed ID: 12525161
[TBL] [Abstract][Full Text] [Related]
8. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
[TBL] [Abstract][Full Text] [Related]
9. "Snapshots" of ispinesib-induced conformational changes in the mitotic kinesin Eg5.
Kaan HY; Major J; Tkocz K; Kozielski F; Rosenfeld SS
J Biol Chem; 2013 Jun; 288(25):18588-98. PubMed ID: 23658017
[TBL] [Abstract][Full Text] [Related]
10. Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration.
Garcia-Saez I; DeBonis S; Lopez R; Trucco F; Rousseau B; Thuéry P; Kozielski F
J Biol Chem; 2007 Mar; 282(13):9740-9747. PubMed ID: 17251189
[TBL] [Abstract][Full Text] [Related]
11. The structural kinetics of switch-1 and the neck linker explain the functions of kinesin-1 and Eg5.
Muretta JM; Jun Y; Gross SP; Major J; Thomas DD; Rosenfeld SS
Proc Natl Acad Sci U S A; 2015 Dec; 112(48):E6606-13. PubMed ID: 26627252
[TBL] [Abstract][Full Text] [Related]
12. A structural model for monastrol inhibition of dimeric kinesin Eg5.
Krzysiak TC; Wendt T; Sproul LR; Tittmann P; Gross H; Gilbert SP; Hoenger A
EMBO J; 2006 May; 25(10):2263-73. PubMed ID: 16642039
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.
Tcherniuk S; van Lis R; Kozielski F; Skoufias DA
Biochem Pharmacol; 2010 Mar; 79(6):864-72. PubMed ID: 19896928
[TBL] [Abstract][Full Text] [Related]
14. Docking and rolling, a model of how the mitotic motor Eg5 works.
Rosenfeld SS; Xing J; Jefferson GM; King PH
J Biol Chem; 2005 Oct; 280(42):35684-95. PubMed ID: 16115880
[TBL] [Abstract][Full Text] [Related]
15. ATPase mechanism of Eg5 in the absence of microtubules: insight into microtubule activation and allosteric inhibition by monastrol.
Cochran JC; Gilbert SP
Biochemistry; 2005 Dec; 44(50):16633-48. PubMed ID: 16342954
[TBL] [Abstract][Full Text] [Related]
16. Loop L5 assumes three distinct orientations during the ATPase cycle of the mitotic kinesin Eg5: a transient and time-resolved fluorescence study.
Muretta JM; Behnke-Parks WM; Major J; Petersen KJ; Goulet A; Moores CA; Thomas DD; Rosenfeld SS
J Biol Chem; 2013 Nov; 288(48):34839-49. PubMed ID: 24145034
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
Kaan HY; Ulaganathan V; Rath O; Prokopcová H; Dallinger D; Kappe CO; Kozielski F
J Med Chem; 2010 Aug; 53(15):5676-83. PubMed ID: 20597485
[TBL] [Abstract][Full Text] [Related]
18. Loop 5-directed compounds inhibit chimeric kinesin-5 motors: implications for conserved allosteric mechanisms.
Liu L; Parameswaran S; Liu J; Kim S; Wojcik EJ
J Biol Chem; 2011 Feb; 286(8):6201-10. PubMed ID: 21127071
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker.
Turner J; Anderson R; Guo J; Beraud C; Fletterick R; Sakowicz R
J Biol Chem; 2001 Jul; 276(27):25496-502. PubMed ID: 11328809
[TBL] [Abstract][Full Text] [Related]
20. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5.
Kapoor TM; Mayer TU; Coughlin ML; Mitchison TJ
J Cell Biol; 2000 Sep; 150(5):975-88. PubMed ID: 10973989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
